XGEVA 120mg Denosumab Injection Amgen Europe
Price: 750 Euro
e-mail: sales@gerovital-gh3.com
tel: +40723141550
 
Indications:
XGEVA contains denosumab, a protein (monoclonal antibody) that works by slowing down bone destruction caused by the spread of cancer to the bones (bone metastases) or giant cell tumor of bone.
XGEVA is used in adults with advanced cancer to prevent serious complications caused by bone metastases (for example, fractures, pressure on the spine, or the need for radiation therapy or surgery).
XGEVA is also used to treat giant cell tumor of bone that cannot be treated with surgery or for which surgery is not the best option, in adults and adolescents who have stopped growing.
Contraindications:
Do not use XGEVA:
- if you are allergic to denosumab or any of the other ingredients of this medicine.
Precautions:
Talk to your doctor or pharmacist before using XGEVA.
Pregnancy, breast-feeding and fertility:
XGEVA has not been studied in pregnant women. It is important to tell your doctor if you are pregnant, think you may be pregnant or are planning to become pregnant. It is not recommended to use
XGEVA if you are pregnant. Women of childbearing potential should use effective contraception during treatment with XGEVA and for at least 5 months after stopping XGEVA.
If you become pregnant during treatment with XGEVA or for at least 5 months after stopping XGEVA, please tell your doctor.
It is not known whether XGEVA is excreted in human milk. It is important to tell your doctor if you are breast-feeding or intend to breast-feed. Your doctor will then help you decide whether to stop breast-feeding or to take XGEVA, taking into account the benefit of breast-feeding for the child and the benefit of XGEVA for the mother.
If you are breast-feeding while taking XGEVA, please tell your doctor.
Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines:
XGEVA has no or negligible influence on the ability to drive and use machines.
Method of administration:
XGEVA should be administered by a healthcare professional.
The recommended dose of XGEVA is 120 mg given as a single injection under the skin (subcutaneously), once every 4 weeks. XGEVA will be injected into the thigh, abdomen or upper arm. If you are being treated for giant cell tumour of bone you will receive an additional dose in the first and second weeks after the first dose.
Do not shake.
You should also take calcium and vitamin D supplements during treatment with XGEVA if you do not have too much calcium in your blood. Your doctor will discuss this with you.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Composition:
- The active substance is denosumab. Each vial contains 120 mg denosumab in 1.7 ml solution (corresponding to 70 mg/ml).
- The other ingredients are glacial acetic acid, sodium hydroxide, sorbitol (E 420), polysorbate 20 and water for injections.
Presentation: 1 vial